Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose donor lymphocyte infusion for EBV-related PTLD after allogeneic HSCT
ChiCTR2400084399Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- May 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor lymphocytes in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Complete response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
donor lymphocytes
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on ChiCTR2400084399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084399.